Read E.V.I.dently Today for current news about health policy and events, among other topics.
E.V.I.dently Today Blog
National Pharmaceutical Council and Anthem Support Health Affairs in Launching New Council on Health Care Spending and Value
NPC launched a broader stakeholder initiative funding research and supporting a series of papers and blog posts in Health Affairs last December. It is in service of this broader mission that NPC, along with Anthem, Inc., is pleased to support the Health Affairs Council on Health Care Spending and Value, which will further advance the all-important health spending dialogue.
According to a new study from the Center for the Evaluation of Value and Risk in Health at Tufts Medical Center and NPC, coverage of specialty medicines by major U.S. commercial health plans varies widely. The study’s findings point to the need for greater transparency in the evidence used to determine plan coverage decisions, given the wide variations in plan coverage and restrictions, and have implications for both patients and providers.
In his latest commentary for Morning Consult, NPC Chief Science Officer Robert W. Dubois explores new research that sheds light on which types of medical care have provided the greatest overall contribution to improvements in patient outcomes during the past several decades -- and raises the possibility that we might actually be under-investing in pharmaceuticals as the most valuable facet of health technology.
An article published on the Health Affairs Blog explores the tensions with paying for gene therapies via online market research with payers and highlights a few proposals to address these concerns.
A single number doesn’t always tell the full story, and that’s the case when it comes to a recent report from AHIP asking how our health care premium dollars are being spent.
With the release of two guidance documents this week, the US Food and Drug Administration took significant steps to modernize how health care information is communicated. The final guidance released by FDA addresses communications questions as well as many of the concerns raised by NPC through our longstanding research in this area and in public testimony and comments.